Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
J Immunol. 2010 Aug 1;185(3):1692-700. doi: 10.4049/jimmunol.0904210. Epub 2010 Jul 9.
Virus-specific CD4(+) T cells optimize antiviral responses by providing help for antiviral humoral responses and CD8(+) T cell differentiation. Although CD4(+) T cell responses to viral infections that undergo complete clearance have been studied extensively, less is known about virus-specific CD4(+) T cell responses to viruses that persistently infect their hosts. Using a mouse polyomavirus (MPyV) infection model, we previously demonstrated that CD4(+) T cells are essential for recruiting naive MPyV-specific CD8(+) T cells in persistently infected mice. In this study, we defined two dominant MPyV-specific CD4(+) T cell populations, one directed toward an epitope derived from the nonstructural large T Ag and the other from the major viral capsid protein of MPyV. These MPyV-specific CD4(+) T cells vary in terms of their magnitude, functional profile, and phenotype during acute and persistent phases of infection. Using a minimally myeloablative-mixed bone marrow chimerism approach, we further show that naive virus-specific CD4(+) T cells, like anti-MPyV CD8(+) T cells, are primed de novo during persistent virus infection. In summary, these findings reveal quantitative and qualitative differences in the CD4(+) T cell response to a persistent virus infection and demonstrate that naive antiviral CD4(+) T cells are recruited during chronic polyomavirus infection.
病毒特异性 CD4(+) T 细胞通过为抗病毒体液反应和 CD8(+) T 细胞分化提供帮助来优化抗病毒反应。虽然已经广泛研究了对完全清除的病毒感染的 CD4(+) T 细胞反应,但对持续感染宿主的病毒的病毒特异性 CD4(+) T 细胞反应知之甚少。使用小鼠多瘤病毒 (MPyV) 感染模型,我们之前证明 CD4(+) T 细胞对于在持续感染的小鼠中招募幼稚的 MPyV 特异性 CD8(+) T 细胞是必不可少的。在这项研究中,我们定义了两种主要的 MPyV 特异性 CD4(+) T 细胞群体,一种针对来自非结构大 T Ag 的表位,另一种针对 MPyV 的主要病毒衣壳蛋白。这些 MPyV 特异性 CD4(+) T 细胞在感染的急性和持续阶段,在其数量、功能谱和表型方面存在差异。使用最小的骨髓混合嵌合体方法,我们进一步表明,幼稚的病毒特异性 CD4(+) T 细胞,就像抗-MPyV CD8(+) T 细胞一样,在持续的病毒感染期间会被从头 primed。总之,这些发现揭示了对持续性病毒感染的 CD4(+) T 细胞反应的数量和质量差异,并表明在慢性多瘤病毒感染期间会招募幼稚的抗病毒 CD4(+) T 细胞。